



Attorney Docket No.: 3500.244-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Junker et al.

Serial No.: 09/592,032

Group Art Unit: 1653

Filed: June 12, 2000

Examiner: Liu, Samuel

Confirmation No: 5100

For: Growth Hormone Crystals

PETITION AND FEE FOR EXTENSION OF TIME (37 C.F.R. 1.136(a))

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

It is respectfully requested that the time for response to the Office Action dated March 11, 2003 be extended for a period of 3 months from June 11, 2003 to September 11, 2003. Applicant(s) hereby petition(s) for such extension of time.

Please charge the required fee, estimated to be \$930, with this application and to credit any overpayments to Novo Nordisk Pharmaceuticals, Inc., Deposit Account No. 14-1447. Please charge any additional fees, should they be required, to Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: September 11, 2003


Richard W. Bork, Reg. No. 36,459
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

09/15/2003 MMEKONEN 00000014 141447 09592032

01 FC:1253 930.00 DA

23650

PATENT TRADEMARK OFFICE


Attorney Docket No.: 3500.244-US
Express Mail Label No.: EV 246876678 US

In making the above disclaimer, disclaimant does not disclaim the terminal part of any patent granted on the above-identified application that would extend beyond the expiration date of the full statutory term of U.S. Patent No. 6,117,984, issued September 12, 2000, in the event that the latter later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued in any matter or is terminated prior to expiration of its full statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

The Commissioner of Patents is hereby authorized to charge the fee required under 37 C.F.R. 1.20(d) for the filing of this Terminal Disclaimer, estimated to be \$110.00, to Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: September 11, 2003


Richard W. Bork, Reg. No. 36,459
Novo Nordisk Pharmaceuticals, Inc.
100 College Road, West
Princeton, NJ 08450
(609) 987-5800

23650

PATENT TRADEMARK OFFICE

110.00 DA
2003.09.11

02 11:12:33
02 11:12:33

2003.09.11